Y-mAbs Therapeutics, Inc. Announces New Interim Analysis of Phase 2 Data for Naxitamab At 2024 Asco Annual Meeting

Y-mAbs Therapeutics, Inc. announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with relapsed or...

Related Keywords

Israel ,United States ,Chicago ,Illinois ,Russia ,Ukraine ,American , ,American Society Of Clinical Oncology ,Y Mabs Therapeutics Inc ,Y Mabs Therapeutics ,Clinical Oncology ,Annual Meeting ,